

Certepetide

Cat. No.:	HY-P3448
CAS No.:	2580154-02-3
Molecular Formula:	C ₃₇ H ₆₀ N ₁₄ O ₁₄ S ₂
Molecular Weight:	989.09
Sequence Shortening:	Ac-CRGDKGPDC-NH2 (Disulfide bridge: Cys1-Cys9)
Target:	Integrin; Complement System
Pathway:	Cytoskeleton; Immunology/Inflammation
Storage:	Sealed storage, away from moisture and light, under nitrogen Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

BIOLOGICAL ACTIVITY

Description	Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors ^{[1][2][3]} .
IC ₅₀ & Target	Alphav-integrins, NRP-1 ^[3] .

REFERENCES

- [1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022
- [2]. Ruoslahti Erkki, et al. Methods for treating pancreatic cancer and other solid tumors. WO2021226148.
- [3]. Andrew Peter Dean, et al. Updated single institution outcome data from the first-in-human CEND-1 trial in metastatic pancreatic cancer. Journal of Clinical Oncology 2021 39:15_suppl, e16274-e16274

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA